PMS-MELOXICAM TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

MELOXICAM

제공처:

PHARMASCIENCE INC

ATC 코드:

M01AC06

INN (국제 이름):

MELOXICAM

복용량:

7.5MG

약제 형태:

TABLET

구성:

MELOXICAM 7.5MG

관리 경로:

ORAL

패키지 단위:

30/100/500

처방전 유형:

Prescription

치료 영역:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

제품 요약:

Active ingredient group (AIG) number: 0131676003; AHFS:

승인 상태:

APPROVED

승인 날짜:

2003-11-06

제품 특성 요약

PRODUCT MONOGRAPH
PR
PMS-MELOXICAM
Meloxicam Tablets, House standard
7.5 mg and 15 mg
NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Ave., Suite # 100
January 19, 2022
Montreal, Quebec
H4P 2T4
www.pharmascience.com
CONTROL NO: 255832
_pms-MELOXICAM Product Monograph Page 2 of 47_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL
USE.........................................................................
3
CONTRAINDICATIONS
.............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
5
ADVERSE REACTIONS
...........................................................................................
16
DRUG
INTERACTIONS............................................................................................
22
DOSAGE AND
ADMINISTRATION.........................................................................
27
OVERDOSAGE
.........................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 30
STORAGE AND
STABILITY....................................................................................
34
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 34
PART II: SCIENTIFIC
INFORMATION..........................................................................
35
PHARMACEUTICAL
INFORMATION.....................................................................
35
CLINICAL TRIALS
...................................................................................................
36
DETAILED PHARMACOLOGY
...............................................................................
39
TOXICOLOGY
...